Page 67 - MemoriaCIBER2019-ENG

CIBEREHD 67
The CIBEREHD Management has promoted a strategic analysis to assess the future of groups dedicated to hepatitis at a time when the cure of hepatitis C is feasible but still requiring research into the mechanisms of progression or regression of the liver disease once the virus has been eliminated.
PROGRAMME 2. Gastrointestinal Physiopathology: inflammatory bowel disease and motility disorders
Coordinator: Pere Clavé Civit
This program includes digestive diseases of great prevalence and impact on the health and quality of life of the pop- ulation, structured in 3 main lines: a) Oesophageal-gastroduodenal pathology; b) Inflammatory Bowel Disease; and c) Neuro-gastroenterology, alterations of digestive motility and functional disorders. Knowledge of the pathophys- iology, diagnosis, epidemiology, prevention and treatment of these diseases is furthered through cooperative and multidisciplinary research among researchers in clinical, basic and epidemiological approaches.
• Oesophageal-gastroduodenal pathology.
The novelties of 2019 in this area focus on the development of pharmacological strategies and strategies for the eradication of helicobacter pylorii infection in cases of resistance to first-line treatments. Also no- teworthy are the publications led by CIBEREHD researchers of the studies from the European Registry on the management of Helicobacter pylori infection (Hp-EuReg), which make it possible to start developing a map of response to treatment and resistances with a European perspective. The study of the adverse effects of non-steroidal anti-inflammatory drugs in peptic disease and its complications (mainly gastroin- testinal bleeding) continues to occupy a relevant place, as well as new studies on the molecular basis of oesophageal-gastric cancer.
• Inflammatory Bowel Disease.
This continues to be the most productive line in this area. Research is aimed at the primary causes of immune dysfunction and recognition of the genetic and environmental determinants conditioning the phenotypic development of each IBD, the development and assessment of new diagnostic methods and methods for monitoring the disease, as well as the development of new treatments. The results for 2019 are very relevant, with the publication of multiple studies and clinical trials comparing the effectiveness and safety of different immune modulation treatments in different stages of the disease (active/) and the appearance of studies evaluating the results of surgical treatment in refractory forms. We also highlight the evaluation of the role of different components of the innate immune system in the pathophysiology and therapeutic potential of IBD. This line also includes research projects related to celiac disease and other diarrheic syndromes of high prevalence about which little is known, such as those arising post-cholecystec- tomy. Celiac disease has gained momentum with the incorporation of an expert group in this disease, and in 2020 a strategic action will be launched to establish epidemiological, diagnostic and follow-up aspects in collaboration with other CIBER areas
• Neuro-gastroenterology, alterations of digestive motility and functional digestive disorders.
These disorders have a prevalence of 15% in the general population. Oropharyngeal Dysphagia (OD) affects 50% of patients who have suffered a stroke, neurodegenerative diseases and frail elderly persons. In 2019, the evaluation of the effect of different dietary and nutritional aspects on oropharyngeal and gastrointestinal function, especially biological and sensory responses to intake, and the role of exclusion